Inactive Instrument

Highlights Versartis Inc Nasdaq

Equities

US92529L1026

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	23-08-02	CI
Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma	23-05-16	CI
Earnings Flash (ARAV) ARAVIVE Posts Q1 Revenue $1.5M	23-05-10	MT
Aravive, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (ARAV) ARAVIVE Reports Q4 Revenue $1.47B	23-03-15	MT
Aravive, Inc. Announces FDA Orphan Drug Designation Granted to Batiraxcept for the Treatment of Pancreatic Cancer	23-02-28	CI
Aravive, Inc. Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian	23-01-04	CI
Aravive's Proposed Kidney Cancer Drug Gets Fast Track Designation From US FDA	22-11-29	MT
Aravive Inc. Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC	22-11-29	CI
Aravive Regains Compliance With Nasdaq's Minimum Bid Price Rule for Continued Listing	22-11-16	MT
Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (ARAV) ARAVIVE Reports Q3 Revenue $5M	22-11-10	MT
Aravive Gets $6 Million Development Milestone from 3D Medicines -- Stock Rises 8% After-Hours	22-10-10	MT
Aravive Receives Third Development Milestone from 3D Medicines	22-10-10	CI
Earnings Flash (ARAV) ARAVIVE Posts Q2 Revenue $1.6M	22-08-11	MT
Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Aravive, Inc. Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma	22-05-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Versartis Inc Nasdaq

Equities

US92529L1026

Highlights

Filters